Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

An investor who sued Verve Therapeutics Inc. for allegedly misleading investors about a clinical trial for its cholesterol medicine has voluntarily dismissed the proposed class action.

Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...

CRISPR Therapeutics AG (CRSP) closed at $43.42 in the latest trading session, marking a -1.83% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.29%. Meanwhile ...

Vertex Pharmaceuticals, best known for its breakthrough cystic fibrosis (CF) treatments, is to become one of the first partners of CRISPR Therapeutics, a leader in new gene-editing technology.

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it ...

CRISPR Therapeutics' lone approved product has billion-dollar potential, while its pipeline also looks exciting. Amgen can make waves in the weight loss market, as well as others, thanks to a ...